Indications in neuroscience and multiple sclerosis : the past; the issues; the future. Andy Smith casts an investor’s eye at neurological disorders, particularly Alzheimer’s disease, Guillian-Barre Syndrome and multiple sclerosis. He looks at why investors find this a difficult area to predict clinical success and explores drug discovery process, interferons and new treatments. A series of expert analysis and commentary on the Life Science sector. Join the discussion; share your views.